AG

AA

bst

ract

s174

Dietary Sulforaphane Ameilorates Dextran Sodium Sulfate-Induced Colitis andEnhances Sulindac-Induced Chemoprotection Against Colon Tumor Formationin MiceSohta Inoue, Atsushi Fukumoto, Risa Sumiyama, Akinori Yanaka

Background and Aims: It has been widely accepted that daily intake of NSAIDs affordschemoprevention against colon cancer. However, long term use of NSAIDs frequently causesserious problems, such as GI bleeding and cerebral vascular events. Thus, it is importantto minimize adverse effects of NSAIDs in cancer chemoprevention. Sulforaphane (SFN), asubstance rich in broccoli sprouts, shows anti-inflammatory effects by activating nrf2-medi-ated NF-κB inactivation (Oncogene, 24:4486, 2005). SFN induces apoptosis of cancer cellsIn Vitro (J Biol Chem 280:19911,2005). Thus, daily intake of dietary SFN may be safe anduseful approach to afford long term chemoprotection against inflammation-related coloncancer. Based on these backgrounds, we hypothesized if SFN could strengthen the chemopro-tective effects of NSAIDs, thereby we may be able to minimize the dose and the durationof NSAIDs for chemoprevention. In the present study, we examined if SFN modulatesNSAID-induced chemoprotection against colitis-associated colon tumor in mice. Methods:C57BL/6 female mice were treated twice with 1% azoxymethane (AOM), followed by for 4days treatment with 3% dextran sodium sulfate (DSS), as previously described. These micewere divided into the following 4 groups. Control Group; No further treatment. Sulindac(SLD) Group: treated with SLD alone. SFN Group; treated with SFN alone. SFN+SLD Group:treated with both SFN and SLD. SLD,160 ppm, was orally administrated during the first 8weeks after the DSS treatment. SFN-rich broccoli sprout juice, which contains 2.5 mmmolSFN, was orally administrated as the with ordinary diet throughout the experimental period.Mice were sacrificed at 8 and 16 wks after the DSS treatment. Degree of colitis, size andnumber of colon tumors were quantitatively evaluated. Antioxidant enzyme activity wasevaluated by measuring GST-P1, and HO-1 expression by real time RT-PCR. Apoptosis andcell proliferation were assessed by immunostaining with TUNEL and PCNA, respectively.Mucosal inflammation was assessed by histology and by measuring mucosal levels of TNF-α and IL-1β mRNA. Results: 1. SLD alone did not affect DSS-induced inflammation, butincreased TUNEL-positive cells, decreased PCNA staining, and inhibited tumor formationin colonic mucosa. 2. SFN alone decreased expression of TNF-α and IL-1β, mitigated DSS-induced colitis, and slightly attenuated tumor formation. 3. SFN + SLD attenuated DSS-induced colitis, and markedly suppressed colon tumor formation. Conclusions: Daily intakeof SFN improves DSS-induced colitis and enhances SLD-induced chemoprevention againstcolon tumor in AOM +DSS treated mice.

175

MTGR1 Modifies the Tumor Microenvironment in the AOM/DSS ColitisAssociated Carcinoma ModelCaitlyn Whitten, Amanda D. Williams, Mary Kay Washington, Rupesh Chaturvedi, KeithT. Wilson, Scott W. Hiebert, Christopher S. Williams

Background: MTGR1 (Myeloid Translocation Gene, Related-1) is a member of a gene familyoriginally identified as targets of chromosomal translocation in acute myeloid leukemia(AML). Analysis of Mtgr1-/- mice revealed a surprising role for MTGR1 in intestinal differenti-ation, proliferation and wound healing programs. We recently reported that MTGs competewith β-catenin for TCF4 occupancy and repress TCF4 mediated transcriptional programs,potentially contributing to the phenotypes described in the Mtgr1-/- mice. Recently, 6 muta-tions have been identified in MTG family members in association with colorectal carcinoma.Based on these observations we hypothesized that MTGR1may modify inflammatory carcino-genesis(CAC) in the colon. Methods: We selected the azoxymethane(AOM)/dextran sodiumsulfate(DSS) rodent model for our studies as this is a robust model for interrogating geneticmodifiers of CAC. 19 Mtgr1-/- and 22 WT mice were injected with 12 mg/kg AOM followedby four cycles of 3% DSS ad lib. At necropsy, colons were isolated and tumor burden anddistribution scored. IHC for BrdU, β-catenin, COX-2, and immune subsets was performed.Tumor RNA was isolated and transcriptome profile generated and analyzed using the PAN-THER suite. Results: Mtgr1-/- mice had fewer and smaller tumors (1.7 vs 7.5 polyps percolon, p<0.001 and 27 vs 82 mm2, p=0.01). There was no difference in intra-tumoralproliferation, but significantly higher apoptosis in Mtgr1-/- tumors, potentially explainingthe difference in tumor burden (32 vs 13 TUNEL (+) cells/HPF, p<0.001). PANTHER analysisof mRNA expression array data revealed significant upregulation of innate and adaptiveimmune networks in the Mtgr1-/- tumors (p<0.001). In support of this observation, in theMtgr1-/- compared to WT tumors, we found increased T-cell infiltrate (49.4 vs 13.6 CD3+

cells/hpf, p<0.001), M1 and M2 macrophages (29.1 vs 14.1 IL-1β+/F4/80+ cells/hpf, p=0.001, and 15.8 vs 7.2 arginase1+/F4/80+ cells/hpf, p=0.003), B-lymphocytes (15.8 vs 6.0B220+ cells/hpf, p<0.0001), regulatory T cells (51.1 vs 25.0 Foxp3+ cells/hpf, p<0.0001),natural killer cells (51.0 vs 36.0 NKp46+ cells/hpf, p=0.003), andmyeloid-derived suppressorcells (13.3 vs 4.3 Gr1+/CD11b+ cells/hpf, p=0.0097). Interestingly, there were fewer dendriticcells and activated dendritic cells in Mtgr1-/- tumors (14.6 vs 23.7 total CD11c+ cells/hpf,p=0.02 and 7.0 vs 19.0 CD11c+/MHCII+ cells/hpf, p=0.04). Conclusions: These studiesprovide evidence that MTGR1 functions as a tumor modifier in intestinal carcinogenesis.We speculate that these effects may occur via modulation of anti-tumor immunity.

176

KrüPpel-Like Factor 5 is a Crucial Mediator of Intestinal Tumorigenesis inMice Harboring Combined APC and KRAS MutationsMandayam O. Nandan, Amr Ghaleb, Beth B. McConnell, Vincent W. Yang

BACKGROUND: Both mutational inactivation of the adenomatous polyposis coli (APC)tumor suppressor gene and activation of the KRAS oncogene are common events in coloncancer. We previously showed that the pro-proliferative transcription factor Krüppel-likefactor 5 (KLF5) is important for mediating transformation upon respective APC inactivationand KRAS activation [Nandan et al. (2008) Gastroenterology 134:120; McConnell et al. (2009)Cancer Res. 69:4125]. AIM: To investigate the In Vivo effect of Klf5 heterozygosity on the

S-32AGA Abstracts

propensity for intestinal tumor formation and target gene expression in mice harboringcombined APC and KRAS mutations. METHODS: ApcMin mice were crossed with Klf5+/- miceto generate double heterozygous ApcMin/Klf5+/- mice. These double heterozygous mice werethen crossed with mice transgenic for an oncogenic KRASV12 under the control of the villinpromoter and the resulting progeny sacrificed at 12 weeks of age. All mice were maintainedon a C57BL/6 background. Intestinal and colonic tissues were collected and prepared forimmunohistochemical analyses for KLF5, β-catenin, cyclin D1, Ki67, pMEK and pERK1/2.RESULTS: At 12 weeks, ApcMin/KRASV12 mice had a 3-fold higher small intestinal adenomaburden than ApcMin mice. The number of tumors per mouse in ApcMin/KRASV12 mice wasreduced on average by 92% when compared to the tri-transgenic ApcMin/KRASV12/Klf5+/-

mice. The tumor number in the tri-transgenic mice was also reduced by 75%when comparedto ApcMin mice. The number of colonic adenomas among the three genotypes was notsignificantly different. The level of Klf5 was elevated in the normal-appearing small intestinalmucosa from both ApcMin and ApcMin/KRASV12 mice compared to wild type mice. Thisincrease was attenuated in the tri-transgenic ApcMin/KRASV12/Klf5+/- mice. There was also adecrease in the levels of β-catenin, cyclin D1 and Ki-67 in the normal-appearing intestinalmucosa of the tri-transgenic mice when compared to the ApcMin/KRASV12 mice. Levels ofpMEK and pERK1/2 were increased in the normal intestinal mucosa of the ApcMin/KRASV12

mice compared to ApcMin and wild type mice. These proteins were modestly reduced in thetri-transgenic mice. Tumor tissues displayed higher levels of Klf5 and β-catenin, irrespectiveof the mouse genotype. CONCLUSIONS: Results of the current study confirm the cumulativeeffect of APC loss and oncogenic KRAS activation on intestinal tumorigenesis. The drasticreduction in tumor burden secondary to Klf5 heterozygosity in ApcMin/KRASV12 mice indicatesa critical function of KLF5 in modulating intestinal tumor formation due to combined APCand KRAS mutations.

177

A Novel Hybrid In Vitro - Orthotopic Transplant Model for Assessment ofExperimental Colon Cancer TherapeuticsLydia Lee, Larissa Georgeon Richard, Michael P. Richardson, Wei Y. Chen, Jatin Roper,Eric S. Martin, Kenneth E. Hung

Careful assessment of experimental therapeutics is crucial prior to clinical trials. Whereasmany discovery programs rely on In Vitro screening of human colon cancer cell lines, thesemay not ultimately translate to robust efficacy in patients. This is not surprising consideringthat many validation studies are performed in xenograft models that transplant high passagecell lines into immunodeficient mice at ectopic sites different from the endogenous colonicmicroenvironment. To address this, we have developed a novel discovery program comprisedof In Vitro screening of low passage mouse colon cancer cell lines followed by In Vivovalidation by orthotopic transplant in the distal colonic mucosa of immunocompetent mice.To generate tumors that are robust surrogates for human sporadic colon cancer, we usedgenetically engineered mouse models similar to those that we have previously described inwhich floxed Apc mice are surgically modified by adenovirus expressing cre recombinase,resulting in discrete tumors restricted to the distal colon. To dissect the efficacy of experi-mental therapeutics in the context of Kras mutant and wild-type tumors, we infected micebearing floxed Apc and p53 alleles (A/P) and an additional latent mutant Kras allele (A/K/P). 13/15 (87%) of the resulting tumors were identified as adenocarcinomas. PCR genotypingconfirmed the inactivation of the Apc and p53 genes in primary A/P colonic tumors andthe additional activation of the latent Kras allele in A/K/P. Western blot analysis demonstratedincreased p-ERK in A/K/P tumors. To generate cell lines, tumors were individually harvestedand enzymatically dissociated. Single cell suspensions and cellular aggregates of isolatedcolonic epithelial cells were plated on collagen-coated dishes; passaged for several weeks toexpand the epithelial tumor cell population under defined media and culture conditions;and assessed for growth, viability, and tumorigenicity. Biochemical and genetic characteriza-tion was performed as with the respective primary tumors. To create an In Vivo orthotopictransplant model, respective tumor cell lines were harvested in log phase growth andtransplanted to the distal colon employing similar protocols as with the adenoviral infection.Colonic tumors were visualized by murine colonoscopy within three weeks. The findingsof combination drug therapy using this composite platform will be presented. In summary,we have developed a hybrid screening program composed of high throughput In Vitroscreening and In Vivo orthotopic transplant in the native colonic environment. These toolsprovide an ideal drug discovery platform for future colon cancer therapeutics.

178

Changing Patterns of Clarithromycin and Metronidazole Resistance AmongstHelicobacter pylori Strains in a Reference CentreAnthony O'Connor, Ikue Taneike, Asghar Qasim, Humphrey J. O'Connor, Barbara M.Ryan, Niall Breslin, Colm A. O'Morain

Introduction: Helicobacter pylori causes much pathology including peptic ulcers and gastriccancer. Eradication rates have fallen over recent years. Antibiotic resistance is thought tobe rising and understanding this phenomenon is important in efforts to eradicate H. pylori.Aims: Antibiotic treatment should be tailored to resistance levels. Our study examined levelsof resistance to metronidazole and clarithromycin in H. pylori isolates in a reference centrein Ireland from 2007 and 2008 and compared them to a similar cohort from a study in 1997.Method: Antimicrobial susceptibilities were tested by E-test. Frequencies of spontaneousmetronidazole and clarithromycin resistance were measured on agar plate containing theantibiotics at concentrations of 2x and 4x MIC value. Clinical data was obtained from charts,laboratory and endoscopy reports. Results: 222 patients were analysed, 98 were females.37 had prior attempts at eradication therapy (all with amoxicillin-clarithromycin-PPI) .31.5% had strains resistant to Metronidazole. 13.2% were noted to have strains resistant toclarithromycin. 8.6% had strains resistant to both agents. Clarithromycin resistance is 9.3%in those who have not had prior eradication therapy compared to 32.4% of those who had.Of those who previously had unsuccessful treatment, 67.6% were sensitive to clarithromycinIn Vitro, suggesting poor compliance is a major factor in failures. Clarithromycin resistanceincreased from 3.9% amongst treatment naive subjects in 1997 to 9.3% in our study,correlating with a 26% increase in the rate of macrolide prescribing for respiratory tract

infections in our population between 2000 and 2005. Metronidazole resistance is 29.1% inthe treatment naive population compared to 43.2% in those who have had prior therapy,even though none had taken metronidazole for H. pylori eradication purposes. Metronidazoleresistance was more likely to occur in females (35.4% vs 28.5%) than males, probablyreflecting greater use of Metronidazole for gynaecologic infection. In 1997 metronidazoleresistance in the treatment-naive cohort was 27.1%. This reflects the fact that metronidazoleuse in the community is static. Conclusion: This study illustrates that resistance to clarithro-mycin amongst Irish patients infected with H. pylori has increased considerably since 1997.The problems of resistance and poor compliance with treatment are intertwined. The futureof treatment may well lie in greater use of culture and sensitivity analysis prior to treatment.This would promote more accurate treatment and given the latency and long term sequelaeof H. pylori infection, this would appear to be the best approach.

179

Quadruple Therapy With Bismuth Subcitrate Potassium, Metronidazole,Tetracycline, and Omeprazole is Superior to Triple Therapy With Omeprazole,Amoxicillin, and Clarithromycin in the Eradication of Helicobacter pyloriPeter Malfertheiner, Francis Megraud, Monique Giguere, Marc Riviere

Background: Helicobacter pylori is associated with a number of conditions including pepticulcer disease (PUD) and dyspeptic symptoms and is the main risk factor for gastric carcinoma.Recommended first-line therapy for H. pylori eradication in Europe is PPI, amoxicillinor metronidazole, and clarithromycin triple therapy given for 7 days. Bismuth-containingquadruple treatments are an alternative first choice. Aim: Compare the rate of H. pylorieradication after quadruple therapy with a single-triple capsule of bismuth subcitrate potas-sium, metronidazole, and tetracycline, given with omeprazole (OBMT) versus omeprazole,amoxicillin, and clarithromycin (OAC) in H. pylori-positive patients with/without presence/history of PUD. Methods: Patients with upper GI symptoms and confirmed H. pylori by C-13 urea breath test (UBT) and rapid urease test with ≥1 of 2 positive results includinghistology and culture were randomized (1:1) to a 10-day course of OBMT or 7-day courseof OAC. Eradication was confirmed by 2 negative UBTs 6 and 10 weeks after treatmentonset. Study was designed for noninferiority, but analysis of superiority was accounted fora priori. Safety and compliance were also assessed. Results: Of 440 patients in the ITTpopulation, 438 received study drug (216 OMBT; 222 OAC), 339 patients were in the PPpopulation. Baseline characteristics including metronidazole (~30%) and clarithromycin(20%) resistance were similar between groups. Compliance was high (>96%) in both groups.Eradication rates were 93.3% (88.5%, 96.5%) with OBMT and 69.6% (61.8%, 76.6%) withOAC in the PP population (P<.001) and 79.8% (73.9%, 84.9%) and 55.4% (48.6%, 62.1%),respectively in the ITT population with imputed data (P<.001). The eradication rate ofOBMT was independent of whether strains were susceptible (95.1%) or resistant (90.5%)to metronidazole at baseline in the PP population (P=.283). The eradication rate of OACwas different in strains resistant to clarithromycin at baseline (8.0%) in the PP populationcompared with susceptible strains (84.9%, P<.001). Both treatments had similar safetyprofiles. About 50% of patients in each group reported an AE with mild to moderate GIcomplaints (dyspepsia, diarrhea, nausea, vomiting) the most frequent (~34% of patients ineach group). Serious AEs were reported in ~2% of patients. Conclusions: H. pylori eradicationrates with OBMT quadruple therapy for 10 days were superior to OAC triple therapy for7 days in patients with/without presence/history of PUD. Safety profiles of the 2 regimenswere similar.

180

Induction of H. pylori Resistance to Metronidazole Through EnhancedExpression of a Bacterial Efflux PumpHitoshi Tsugawa, Hidekazu Suzuki, Hiroe Muraoka, Sachiko Suzuki, Kenro Hirata,Juntaro Matsuzaki, Yoshimasa Saito, Toshifumi Hibi

Background.Metronidazole (Mtz) is an important component of H. pylori eradication regi-mens. Mtz enters the cells by diffusion; its antimicrobial toxicity is dependent on thereduction of its nitro group to nitro anion radicals and generation of superoxide radicals.Since NADPH nitroreductase (RdxA) of H. pylori reduces the nitro group of Mtz to activemetabolities that produce DNA strand breaks and oxidative stress, ultimately causing rapidcell death, mutational inactivation of the rdxA gene may be expected to be associated withthe development of resistance to Mtz (Mol. Microbiol. 28:383-93, 1998). However, wepreviously isolated Mtz-resistant strains with an intact RdxA protein (Aliment. Pharmacol.Ther. 24:81-7, 2006), strongly suggesting the existence of a mechanism other than RdxAinactivation for Mtz resistance. The present study was designed to examine the mechanismof acquisition of resistance of H. pylori to Mtz other than RdxA inactivation In Vitro.Methods.Mtz-susceptible H. pylori strains (KS0309, KS0313, KS0317, KS0318, KS0329, KS0330,KS0371, KS0372, KS0381 and KS0391) were used. To induce Mtz resistance In Vitro,the Mtz-susceptible strains were cultured on blood agar plates containing sub-inhibitoryconcentrations of Mtz, with 10 passages every 3 days. The mRNA expression of the genesencoding the efflux pump (HP0605-HP0607, HP0969-HP0971, HP1327-HP1329 andHP1487-HP1489) in the bacteria under Mtz exposure was measured by quantitative RT-PCR, and compared between the susceptible strains and the induced Mtz-resistant strains.Results.Mtz-resistance was induced In Vitro in 10 Mtz-susceptible strains, with MICs rangingfrom 0.5 to 1 μg/mL. After 10 passages of Mtz-susceptible strains on blood agar platescontaining sub-inhibitory concentrations of Mtz, the MICs increased to levels seen for theMtz-resistant strains (MIC>8 μg/mL) in 9 of the strains (8-64 μg/mL). The mRNA expressionlevels of the bacterial efflux pump in the Mtz-susceptible strains were scarcely induced inthe presence of under 0.5 μg/mL Mtz. In contrast, the mRNA expression levels of HP0605and HP1327 in the Mtz-resistant strains increased by about 1.2-1.9 fold (p<0.05) and 1.3-4.6 fold (p<0.05), respectively, in the presence of 0.5 μg/mL Mtz. These results show thatMtz-resistant strains acquire the ability for enhanced expression of HP0605 and HP1327 inresponse to Mtz exposure. Conclusion. Overexpression of two efflux pump genes (HP0605and HP1327) is an initial step in the acquisition of Mtz resistance in H. pylori.

S-33 AGA Abstracts

181

Antibiotic Susceptibility Patterns in Helicobacter pylori in 1617 PatientsPerforming an EGDSLuigi Gatta, Nimish B. Vakil, Chiara Ricci, Federico Perna, Ilaria M. Saracino, ValentinaCastelli, Giulia Fiorini, Francesco Di Mario, Dino Vaira

Background: Antimicrobial resistant strains of Helicobacter pylori (H. pylori) have been increas-ing worldwide, and it has been speculated that this may account for progressive decreasein eradication rates reported in the literature. It is therefore clinical and microbiologicallyuseful to periodically survey the prevalence of resistant strains for the most frequently usedantibiotics used in the eradication treatment. Aim: To assess the prevalence of resistantstrains to metronidazole (M), clarithromycin(C), and levofloxacin (L) in a cohort of patientsperforming an EGDS for dyspeptic symptoms in Italy. Methods: Between 2007 and 2009,1617 patients (M/F: 39.5%/60.4%; median age: 52 years; 25th and 75th: 40 and 62 yearsrespectively) underwent upper endoscopy and a biopsy sample was also obtained to performculture and an In Vitro antimicrobial susceptibility testing. Susceptibility testing was per-formed by epsilometer test (Etest) and the following MIC breakpoints were used: resistanceto C (>1 microgram/ml); resistance to M (>8 microgram/ml), and resistance to L (> 1microgram/ml). Results: 773 out of 1617 patients were H. pylori positive (47.8%), andculture was available for the 92% of the infected patients. Resistance to: M was found in61% of the strains, C in 47.1% of the strains, and L in 18.3% of the strains. Double resistanceto: C+M was found in 36.5% of the strains; C+L in 11.3% of the strains; and M+L in 14.7%.10.2% of the strains were resistant to M+C+L. Considering resistance to a single antibiotic,resistance to M was more frequent in women (p<0.001); considering the double resistance,women were also more likely to have resistance to both antibiotics in CM group (p<0.001),CL group (p=0.0005), and ML group (p=0.01); women were finally more probable toharbour strains also resistant to all 3 antibiotics tested (p=0.004). Conclusions: 1. Theprevalence of strains resistant to Clarithromycin and Metronidazole is now very high account-ing for the poor results with conventional triple therapy. 2. Levofloxacin resistance hasreached 18% making it unlikely that this frequently used salvage regimen will be effectivein the future. New treatment regimens and new anti-microbial agents are urgently needed.

182

Test, Treat and Re-Test. Who is Best at Checking for Helicobacter pyloriEradication After Apositive Urea Breath Test (UBT), Family Physicians orGastroenterologists?Anthony O'Connor, Niall R. O'Moráin, Mark Dobson, Asghar Qasim, Barbara M. Ryan,Niall Breslin, Humphrey J. O'Connor, Colm A. O'Morain

Introduction: Helicobacter pylori infection causes dyspepsia, peptic ulcers and is a class Icarcinogen. Urea breath test is an accurate and non-invasive test used to diagnose H. pyloriinfection. Current guidelines require re-testing to confirm eradication once infection hasbeen diagnosed and treatment administered. Aims: To assess the adherence of healthcareproviders to ensuring eradication confirmation checks are organised after a positive UBT.Method: 545 patients underwent 13-C UBT testing for the investigation of dyspepsia. Baselineand 15-min gas samples after ingestion of 100 mg 13C-labeled urea were analyzed for excess13CO2/12CO2 ratio (ECR). A cut off point of 4.0 was used to diagnose persistent H. pyloriinfection. 160 (29.8%) were subsequently diagnosed with H. pylori infection. Clinical anddemographic Data was gathered from endoscopy reports, patient charts and pathologyreports. Results: 174 patients had been referred by gastroenterologists for UBT followingdyspepsia consultations without endoscopy, median age 35, 71 males(40.8%). 371 werereferred by family physicians, median age 40, 148 males (39.9%). 35.6% of those referredby gastroenterologists and 26.4% of those referred by family physicians had positive tests.Of 62 patients referred by gastroenterologists who turned out to have a positive UBT 62.9%had eradication checks organised. Of the 98 patients with positive UBT having been referredfrom family physicians 54.6% subsequently had eradication checks organised. Conclusion:Patients referred from gastroenterology clinics with dyspepsia are more likely to have positiveUBTs than those referred from family physicians. There is much failure to adhere to test, treatand re-test policies which has been replicated in other studies, however gastroenterologists aremore likely to comply with these guidelines than family physicians.

183

Glutathione Peroxidase-7: An Epigenetically Silenced Gene With DualFunctions in Esophageal AdenocarcinomasDunFa Peng, Tian-Ling Hu, Regine Schneider-Stock, Rupesh Chaturvedi, Keith T. Wilson,Wael M. El-Rifai

Background: Chronic gastroesophageal reflux disease is a major risk factor in the developmentof Barrett's esophagus (BE) and subsequent progression to EACs. Progressive accumulationof reactive oxygen species and subsequent oxidative DNA damage has been reported in BEand EACs. The glutathione peroxidase (GPX) family members protect against oxidative stressby scavenging and inactivating hydrogen and lipid peroxides to water or lipid hydroxyls ina glutathione-dependent reductive reaction. GPX7 is a recently identified GPX with unknownbiological functions. Methods and Results: We examined GPX7 gene promoter methylationusing quantitative Pyro-sequencing technology. None of 37 normal samples, 2 of 11 BE, 7of 11 Barrett's dysplasia (P<.001), and 67 of 106 EACs (P<.001) showed promoter DNAhypermethylation. The DNA hypermethylation correlated with the down-regulation of GPX7expression (P<.01). Three of four EAC cell lines showed methylation of GPX7 and hadstrong expression of DNMT1 and DNMT3b as compared with two BE cell lines. QuantitativeChIP assay of histone modifications along the GPX7 promoter using antibodies specific forH3K9ac, H3K9me, and H3K4me followed by qPCR confirmed the presence of a higherlevel of the repressor histone code (H3K9me) than the activator codes (H3K9ac andH3K4me)in the EAC cell lines. An opposite finding was true in the BE cells. Treatment of EAC cellswith 5-Aza led to demethylation of the GPX7 promoter and re-expression of the GPX7. Were-constituted GPX7 expression in two EAC lines (OE33, FLO-1). Cells stably expressingGPX7 had more than four-fold reduction in growth rate as compared to vector controls.

AG

AA

bst

ract

s